13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001831942
Total reported value
$1.7B
$1.7B
36 檔
35.3%
At the close of Q3 2024, Commodore Capital LP disclosed equity holdings valued at approximately $1.7B, spread across 36 reported holdings.
In Q3 2024, Commodore Capital LP displayed an active expansion posture, initiating 4 new positions and adding to 12 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including MERUS N V, VERA, XENE) accounted for 35.3% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | Stock-Other | 10.46% | — | +4.69% | |
| 2 | VERA | Vera Therapeutics Inc | Stock-Other | 6.84% | — | — | |
| 3 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 6.64% | -2.78% | EXIT | |
| 4 | PCVX | Vaxcyte Inc | Stock-Other | 6.57% | — | -29.50% | |
| 5 | ELVN | Enliven Therapeutics Inc | Stock-Other | 6.54% | +2.47% | +3.19% | |
| 6 | NUVL | Nuvalent Inc-a | Stock-Other | 6.01% | -4.20% | -36.82% | |
| 7 | COGT | Cogent Biosciences Inc | Stock-Other | 5.09% | +0.60% | -22.57% | |
| 8 | ALKS | Alkermes plc | Stock-Healthcare | 5.07% | +0.77% | +110.91% | |
| 9 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.98% | -1.26% | EXIT | |
| 10 | SYRE | Spyre Therapeutics Inc | Stock-Other | 3.65% | -1.10% | — | |
| 11 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.63% | — | +0.87% | |
| 12 | CLDX | Celldex Therapeutics Inc | Stock-Other | 3.44% | -1.96% | +13.61% | |
| 13 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 2.84% | — | +11.95% | |
| 14 | CATX | Perspective Therapeutics Inc | Stock-Other | 2.79% | -0.24% | -28.07% | |
| 15 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.32% | -2.04% | EXIT | |
| 16 | PHVS | Pharvaris N.V. | Stock-Other | 2.21% | -0.21% | +5.59% | |
| 17 | KURA | Kura Oncology Inc | Stock-Other | 2.20% | — | +12.97% | |
| 18 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 2.13% | — | -46.94% | |
| 19 | ORKA | Oruka Therapeutics Inc | Stock-Other | 2.10% | — | — | |
| 20 | ARVN | Arvinas Inc | Stock-Other | 1.85% | — | -36.32% | |
| 21 | CELC | Celcuity Inc | Stock-Other | 1.42% | — | +3.98% | |
| 22 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.35% | — | — | |
| 23 | NKTX | Nkarta Inc | Stock-Other | 1.32% | — | +12.31% | |
| 24 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.28% | — | — | |
| 25 | CCCC | C4 Therapeutics Inc | Stock-Other | 1.21% | — | — | |
| 26 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.15% | — | -11.96% | |
| 27 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.06% | — | +7.27% | |
| 28 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.06% | — | — | |
| 29 | ABVX | Abivax Sa-adr | Stock-Other | 0.92% | — | — | |
| 30 | TIL | Instil Bio Inc | Stock-Other | 0.63% | — | — | |
| 31 | NGNE | Neurogene Inc | Stock-Other | 0.52% | — | — | |
| 32 | ✓ | Stock-Other | 0.47% | — | — | ||
| 33 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.33% | — | — | |
| 34 | CABA | Cabaletta Bio Inc | Stock-Other | 0.32% | — | — | |
| 35 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.30% | +0.04% | NEW | |
| 36 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.29% | +0.70% | +1107.50% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ALKS | Alkermes plc | +2.8% | +110.91% | Add |
| 2 | NRIX | Nurix Therapeutics Inc | +2.3% | NEW | New buy |
| 3 | ORKA | Oruka Therapeutics Inc | +2.1% | NEW | New buy |
| 4 | VRDN | Viridian Therapeutics Inc | +1.4% | +0.87% | Add |
| 5 | 260 | Centessa Pharmaceuticals-adr | +1.4% | NEW | New buy |
| 6 | VERA | Vera Therapeutics Inc | +0.7% | — | Unchanged |
| 7 | TIL | Instil Bio Inc | +0.6% | NEW | New buy |
| 8 | SYRE | Spyre Therapeutics Inc | +0.5% | — | Unchanged |
| 9 | ORIC | Oric Pharmaceuticals Inc | +0.3% | — | Unchanged |
| 10 | APGE | Apogee Therapeutics Inc | +0.3% | — | Unchanged |
| 11 | AVTX | Avalo Therapeutics Inc | +0.3% | +1107.50% | Add |
| 12 | ELVN | Enliven Therapeutics Inc | +0.2% | +3.19% | Add |
| 13 | CCCC | C4 Therapeutics Inc | +0.1% | — | Unchanged |
| 14 | NGNE | Neurogene Inc | 0% | — | Unchanged |
| 15 | SLNOEUR | Soleno Therapeutics Inc | 0% | -11.58% | Trim |
| 16 | ✓ | Helix Acquisition CORP Ii | 0% | — | Unchanged |
| 17 | KURA | Kura Oncology Inc | 0% | +12.97% | Add |
| 18 | ✓ | -0.1% | — | Unchanged | |
| 19 | VTGN | Vistagen Therapeutics Inc | -0.1% | — | Unchanged |
| 20 | SNDX | Syndax Pharmaceuticals Inc | -0.1% | +7.27% | Add |
| 21 | ABIOEUR | Arca Biopharma Inc | -0.1% | EXIT | Sold out |
| 22 | PHVS | Pharvaris N.V. | -0.1% | +5.59% | Add |
| 23 | PCVX | Vaxcyte Inc | -0.2% | -29.50% | Trim |
| 24 | CLDX | Celldex Therapeutics Inc | -0.2% | +13.61% | Add |
| 25 | ✓ | Third Harmonic Bio Inc | -0.2% | -11.96% | Trim |
| 26 | CELC | Celcuity Inc | -0.2% | +3.98% | Add |
| 27 | CABA | Cabaletta Bio Inc | -0.2% | — | Unchanged |
| 28 | ABVX | Abivax Sa-adr | -0.2% | — | Unchanged |
| 29 | AUTL | Autolus Therapeutics PLC | -0.3% | EXIT | Sold out |
| 30 | NKTX | Nkarta Inc | -0.4% | +12.31% | Add |
| 31 | CATX | Perspective Therapeutics Inc | -0.4% | -28.07% | Trim |
| 32 | COGT | Cogent Biosciences Inc | -0.5% | -22.57% | Trim |
| 33 | BRD1EUR | Mind Medicine Mindmed Inc | -0.7% | +11.95% | Add |
| 34 | XENE | Xenon Pharmaceuticals Inc | -0.7% | -1.97% | Trim |
| 35 | RYTM | Rhythm Pharmaceuticals Inc | -1.3% | -46.94% | Trim |
| 36 | IMVT | Immunovant Inc | -1.4% | EXIT | Sold out |
| 37 | ARVN | Arvinas Inc | -1.6% | -36.32% | Trim |
| 38 | NUVL | Nuvalent Inc-a | -1.7% | -36.82% | Trim |
| 39 | ✓ | Merus N V | -2.5% | +4.69% | Add |
According to official SEC Form 13F filings, Commodore Capital LP reported a total U.S. public equity portfolio value of $1.7B across 36 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
NRIX
市值: $37.1M
Top Position Liquidated / Trimmed
IMVT
前期市值: $19.8M
During Q3 2024, Commodore Capital LP's top holdings by market value included MERUS N V (10.5%)、VERA (6.8%)、XENE (6.6%). The largest single position, MERUS N V, represented 10.5% of total portfolio value.
In Q3 2024, Commodore Capital LP made 28 total portfolio adjustments, initiating 4 new buys, adding to 12 positions, trimming 9 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.